Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 29, 2022 08:00 ET | Source: Immutep Limited

Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer

New collaboration builds on encouraging clinical data previously reported from INSIGHT-004 in multiple solid tumour indications from the combination of eftilagimod alpha (“efti”) and avelumab...
November 14, 2022 08:00 ET | Source: Immutep Limited

Immutep Receives Australian R&D Tax Incentive

Media Release (Code: ASX: IMM; NASDAQ: IMMP) SYDNEY, AUSTRALIA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce...
November 10, 2022 11:10 ET | Source: Immutep Limited

Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting

Media Release Overall response rate (ORR) increases to 40.4%, according to iRECIST, in TACTI-002 all-comer PD-L1 Phase II trial in 1st line non-small cell lung cancer (1L NSCLC) ORR improved across...
November 10, 2022 09:00 ET | Source: Immutep Limited

Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022

Media Release First activity evaluation of efti as part of triple combination therapy yields promising early results with 72.7% response rate and 90.9% disease control rate in 1st line NSCLC...
November 09, 2022 08:00 ET | Source: Immutep Limited

Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination

Media Release SYDNEY, AUSTRALIA, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...
November 04, 2022 08:00 ET | Source: Immutep Limited

Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference

Late-breaking abstract one of nine abstracts selected by SITC Communications Committee to be showcased at the SITC 2022 Press Conference Company to host Webcast on Thursday, 10th November...
November 02, 2022 08:00 ET | Source: Immutep Limited

Immutep Late-Breaking Abstract Accepted for Oral Presentation on First-in-Class LAG-3 Therapeutic Eftilagimod Alpha at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Media Release SYDNEY, AUSTRALIA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company...
November 01, 2022 19:59 ET | Source: Immutep Limited

Immutep to Participate in Two Upcoming Investor Conferences

Media Release SYDNEY, AUSTRALIA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...
October 26, 2022 08:00 ET | Source: Immutep Limited

Immutep Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned

Media Release SYDNEY, AUSTRALIA, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...
October 25, 2022 08:00 ET | Source: Immutep Limited

Immutep Quarterly Activities Report

Media Release Clinical development strategy for efti to prioritise non-small cell lung cancer (NSCLC), as well as advance head & neck squamous cell cancer (HNSCC) and metastatic breast cancer...